my research goal today was to explore whether this stock presents a buying opportunity for those building a diversified ...

The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab ... at the American Society of Hematology ...

The firm owned 44,289 shares of the company’s stock after acquiring an additional 8,494 shares during the quarter. Crossmark ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

Sanofi has currently 36 potential new medicines and vaccines in its pipeline. In European morning trade, the stock rose 1.5% ...

Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...

Sanofi (NASDAQ:SNY – Free Report) by 30.4% during the third quarter, according to the company in its most recent filing with ...

That meant a mixed quarter for Sanofi. While analysts tracking the stock were collectively modeling a notably higher sales figure of almost 14.3 billion euros ($15.4 billion), they very much ...

Vandana Singh Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 ...

Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in ...